Despite these positive clinical developments, Amgen and Viking Therapeutics have performed poorly on the stock market in the past 12 months, though progress in this area might eventually help them ...

Image source: Getty Images. Amgen's leading weight loss candidate is called MariTide. In November, the biotech reported that in a phase 2 study, the medicine led to an average weight loss of about ...

Amgen's leading weight loss candidate is called MariTide. In November, the biotech reported that in a phase 2 study, the medicine led to an average weight loss of about 20% in overweight or obese ...

From a valuation standpoint, Amgen is reasonably priced. Going by the price/earnings ratio, the company’s shares currently trade at 13.12 forward earnings, which is lower than 14.74 for the industry.

At current levels, we believe AMGN scores above BMY, buoyed by solid fundamentals and recent positive estimate revisions.

Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in – but the highly anticipated doesn't seem to have lived up to investor expectations. MariTide (maridebart ...

Viking Therapeutics' VENTURE-Oral study of VK2735 has completed enrollment, with a readout set for H2'25. Learn why VKTX ...

MariTide is moving very quickly ... And certainly, with respect to your experience at Amgen and the position that you have in the organization, you take a very unique view and experience that ...